E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers [Active immunization of infants against gastroenteritis (GE) due to rotavirus (RV)]. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To evaluate non-inferiority of GSK Biologicals' HRV liquid vaccine compared to GSK Biologicals' HRV lyophilized vaccine in terms of geometric mean concentrations (GMCs) for anti-RV antibodies, one month post dose 2 of HRV liquid vaccine and HRV lyophilized vaccine
- Criterion: Non-inferiority will be stated if the lower limit of the two-sided 95% confidence interval (CI) for the ratio of anti RV IgA antibody GMCs between HRV liquid vaccine over the HRV lyophilized vaccine, one month after dose 2 is greater than or equal to 0.5. |
|
E.2.2 | Secondary objectives of the trial |
1)To assess the immunogenicity of the HRV liquid vaccine and HRV lyophilized vaccine, in terms of seroconversion* rates, one month post dose 2 of HRV vaccine
*Seroconversion is defined as: for subjects with a pre-vaccination anti-RV IgA antibody concentration <20 U/mL, seroconversion is achieved when the post-vaccination concentration is ≥20 U/mL; for subjects with a pre-vaccination anti-RV IgA antibody concentration ≥20 U/mL, seroconversion is achieved when the post-vaccination concentration is ≥2 times the pre-vaccination concentration
2)To assess the reactogenicity of the HRV liquid vaccine and the HRV lyophilized vaccine in terms of solicited adverse events (AEs), during the 8-day (Day 1–Day 8) follow-up period after each vaccination
3)To assess the safety of the HRV liquid vaccine and the HRV lyophilized vaccine in terms of unsolicited AEs, during the 31-day (Day 1–Day 31) follow-up period after each vaccination and serious adverse events (SAEs), during the entire study period |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Subjects’ parent(s)/ Legally Acceptable Representative (s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
• Written informed consent obtained from the parent(s)/ LAR(s) of the subject prior to performing any study specific procedure.
• A male or female between, and including, 6 and 10 weeks of age at the time of the first vaccination.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• Birth weight >2000 grams.
|
|
E.4 | Principal exclusion criteria |
• Child in care.
• Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccine (Day-29 to Day 1), or planned use during the study period.
• Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
• Administration of any chronic drug therapy to be continued during the study period.
• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine administration and ending at Visit 3; with the exception of the inactivated influenza vaccine, which is allowed at any time during the study, and other licensed routine childhood vaccinations, according to the local immunization practice.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
• History of confirmed RV GE.
• Previous vaccination against RV.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, (including Severe Combined Immunodeficiency [SCID] disorder) based on medical history and physical examination.
• Uncorrected congenital malformation (such as Meckel’s diverticulum) of the gastrointestinal tract that would pre-dispose for Intussusception (IS).
• History of IS.
• Very prematurely born infants (born ≤28 weeks of gestation).
• Hypersensitivity to latex.
• Family history of congenital or hereditary immunodeficiency.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
• Major congenital defects or serious chronic illness.
• History of any neurological disorders or seizures.
• Acute disease and/or fever at the time of enrolment. This warrants deferral of vaccination.
- Fever is defined as temperature >= 38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity, the axilla or the rectum.
- Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
• Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or medical history.
• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
• Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).
• GE within 7 days preceding the study vaccine administration (warrants deferral of the vaccination)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Anti-rotavirus (Anti-RV) immunoglobulin A (IgA) antibody concentrations |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
One month post Dose 2 (Month 2; Visit 3) of HRV liquid vaccine and HRV lyophilized vaccine |
|
E.5.2 | Secondary end point(s) |
1) Percentage of seroconverted subjects for anti-RV IgA antibody
2) Number of subjects reporting any solicited general adverse events (AEs)
3) Number of subjects reporting any unsolicited AEs
4) Number of subjects reporting any serious adverse events (SAEs) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) One month post Dose 2 (Month 2; Visit 3) of HRV liquid vaccine and HRV lyophilized vaccine
2) During the 8-day (Day 1-Day 8) follow-up period, after each dose of HRV liquid vaccine and HRV lyophilized vaccine.
3) During the 31-day (Day 1-Day 31) follow-up period, after each dose of HRV liquid vaccine and HRV lyophilized vaccine.
4) Throughout the study period (Dose 1 [Day1, Visit 1] up to study end [Month 2; Visit 3]). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last testing results released for samples collected at Visit 3. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 13 |